LentiStem Biotech 

“Next-generation of gene-based therapies”

OWNER

Carlos Blanco Benítez (See Profile)


Sector

Cancer therapeutics

Stage

Prototyping, preclinical

Country

Spain


Patented Technology

Expected marked entry

New cancer immunotherapies

IP Type Status Time Countries Link Coverage
Patent Approved
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Switzerland
  • USA
Link Claims

1. A polynucleotide comprising i) a nucleotide sequence encoding a specific chimeric antigen receptor (CAR) and ii) a promoter from the Wiskott-Aldrich syndrome locus or a fragment of said promoter comprising SEQ ID NO 2 or a nucleotide sequence having at least 70% identity with SEQ. ID NO 2, wherein said promoter is operably linked to the nucleotide sequence encoding the CAR in order to drive the expression of the chimeric antigen receptor, and wherein the CAR comprises at least one extracellular ligand binding domain, a transmembrane domain and at least one intracellular signalling domain.

2. The polynucleotide of claim 1, wherein the promoter comprises SEQ ID NO 1 or a nucleotide sequence having at least 70% identity with SEQ ID NO 1.

3. The polynucleotide of claim 1, wherein the promoter is SEQ ID NO 1.

4. An expression vector comprising the nucleic acid of any of claims 1 to 3.

5. The expression vector of claim 4, wherein said expression vector is a viral vector.

6. The viral vector of claim 5, wherein said viral vector is a lentiviral vector.

7. Immune cells expressing at the cell surface membrane a specific chimeric antigen receptor comprising at least one extracellular ligand binding domain and at least one intracellular signalling domain wherein said Immune cells are transduced with theviral expression vector of any of claims 5 to 6.

8. Immune cells expressing at the cell surface membrane a specific chimeric antigen receptor comprising at least one extracellular ligand binding domain and at least one intracellular signalling domain wherein said chimeric antigen receptor is expressed by the expression vector of claim 4.

9. The immune cells according to any one of claims 7 to 8 derived from inflammatory T- lymphocytes, cytotoxic T-lymphocytes, regulatory T- lymphocytes or helper T- lymphocytes.

10. The immune cells according to any one of claims 7 to 9, wherein the cells are recovered from donors.

11. The immune cells according to any one of claims 7 to 8, wherein the cells are recovered from patients.

12. The immune cells according to any one of claims 7 to llfor use in therapy.

13. The immune cells according to any one of claims 7 to 11 for use in the treatment of cancer, such as neoplasias, B-cell neoplasias, lymphoma or leukaemia, or multiple myeloma.

This information is confidential, do not share or copy.

Under evaluation at least till: 6th May

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2021 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar